Audit: QRS - Ecklonia cava for Health & Longevity

Audit conducted on 18/08/2026 02:02 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol doses (72–144, 600–1,500, 500 mg) trace to ER lines 377–381; all 15 monitoring rows match the ER table lines 474–488; all gate items trace to ER lines 325–353.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“exceeds the regulatory intake ceiling” (action_2_sub) mirrors ER line 379; “less certain reductions” in at_a_glance mirrors ER line 527.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain the ER’s absolute framing; interactions remain cautions, matching ER lines 325–343.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gate items come only from Key Interactions & Contraindications; no Benefit- or Risk-Modifying Factor is surfaced anywhere.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, NCT identifiers, author names, or product brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, non-promotional register carried over from the ER Conclusion and Protocol sections.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified thresholds and functional ranges sit alongside plain-language framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as evidence and ranges, not orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No directive verbs in the document’s own voice; the only “must” is inside an unmodified CSS comment (line 130).
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of “recommend”, “advise”, or equivalent.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained only where they are load-bearing decision gates (e.g., Child-Pugh Class B or C, eGFR thresholds).
2.8	Information is presented in a concise and very compact manner	🟢	Every gate, benefit, and risk item is reduced to its key fact; trailing rationale from the ER is stripped throughout.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for second-person address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges (e.g., fasting insulin <5 µIU/mL, hs-CRP <0.5 mg/L) rather than conventional cut-offs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	15-marker panel including species-resolved urinary arsenic and urinary iodine assumes an effortful reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	at_a_glance surfaces seller-run trials and low trial quality, the decisive signal for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging”; the speculative benefit uses the ER’s “slower cognitive aging”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology throughout; the plain-language register in at_a_glance is required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate heads, tier labels, and column headers are byte-identical to the template.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names present; marker_#* and qualitative_item# correctly expanded to 15 and 6 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows changes confined to checklist-addressed spans and the metadata block.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the empty Benefits High tier is governed by item 12.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3_label reproduce “Standard supplement protocol”, “Glycemic protocol”, “Sleep protocol” verbatim from ER lines 377–381.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels derive from ER line 440 wording; monitoring marker names reproduce the ER table column verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text emoji scan returns nothing; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to key facts; no section is expanded beyond the mandated content of items 8.2, 9.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the preceding title text is permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no element repeats the values.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: ecklonia_cava_2026-0825-2243_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0818-0141.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All nine keys parse cleanly; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Ecklonia cava for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Ecklonia cava for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/18/2026”, matching qrs_creation_date 2026-0818-0141.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block (lines 415–428) is structurally identical to the template.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 527–531: measured effect, evidence quality, and the two governing hazards.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Extract framing ← line 527; seller-run and low quality ← line 529; iodine and arsenic ← line 531.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“blood-sugar rise”, “starchy meal”, “night-time wakefulness” replace glycemic/postprandial terminology; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size, or p-value.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimate appears.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the “Populations who should avoid Ecklonia cava” list, ER lines 345–353.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER populations present, in ER order.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven well-formed <li> elements, lines 569–582.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All em-dash clauses stripped (e.g., “— no human safety data”, “— any iodine-bearing form, purified or whole-alga”); no dash remains in the span.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Retains 60 IU/mL, 300 µg/L, 100 × 10⁹/L, 7 days, Child-Pugh Class B or C, and eGFR below 30 mL/min/1.73 m².
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from ER lines 325–343.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interaction bullets present, in ER order; no overlap with the contraindication list.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten well-formed <li> elements, lines 590–616.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All “caution — …” rationale and “Mitigation: …” clauses stripped; mechanistic glosses such as “they block starch digestion” removed; no dash remains in the span.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every named drug is retained (glimepiride/glipizide/gliclazide, acarbose/miglitol, sitagliptin/semaglutide, methimazole/propylthiouracil, lorazepam/zolpidem/gabapentin/pregabalin, warfarin/apixaban/clopidogrel/aspirin, and the full supplement lists).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten such interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Sourced from the ER Therapeutic Protocol, lines 377–381.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three dosing regimens (standard, glycemic, sleep) are the ER’s own three leading actionable bullets.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable aspects; no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: 72–144 mg/day, 600–1,500 mg/day, 500 mg, each with the ER’s form, timing and duration detail.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Post-meal glucose and lipids/body fat/blood pressure from ER line 440; sleep maintenance from ER lines 175–177.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Post-meal glucose (Medium tier) first, lipids/body fat/blood pressure (Medium and Low) second, sleep maintenance (Low) third.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“Immediate” / “12 weeks” / “1 week” with ER-derived sub-text in each case.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (line 440).

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every item corresponds to an ER Expected Benefits sub-heading, lines 153–227.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present, lines 540–559.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to bare sub-heading facts; magnitudes, confidence intervals and conflict-of-interest notes all dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content remains in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER’s High tier holds no benefit (line 155); benefits_high is emptied and set to style="display: none" at line 540.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every item corresponds to an ER Potential Risks & Side Effects sub-heading, lines 253–303.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated, lines 628–650.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to bare sub-heading facts; the ER’s Magnitude paragraphs and citations are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content remains in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Sourced from the ER Monitoring Protocol & Defining Success table, lines 472–488.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 15 ER biomarkers present, in ER order, with names, optimal ranges and rationale reproduced verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 865: baseline, two weeks of post-meal readings, 8–12 weeks, 6–12 months, urinary iodine at 12 weeks then annually, coagulation within two weeks — all from ER line 470.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Sourced from the qualitative marker list at ER lines 490–497.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present, in ER order, lines 877–901.

Issues 18/08/2026 02:02

Pass rate 100.00%. No issues found.

Issues 18/08/2026 01:55

1. 4.5 — Qualitative and cadence text not condensed: The six Qualitative Assessment items (lines 878–912) are carried over at near-full ER length with their explanatory trailing clauses, and monitoring_cadence (lines 865–870) reproduces the ER’s 274-character retest paragraph almost verbatim, so neither section was condensed to the one-page per-section budget.

Fixes 18/08/2026 01:55

1. 4.5 — Qualitative items condensed: Stripped the explanatory trailing clauses from all six Qualitative Assessment items (e.g., “Waist circumference measured monthly, which tracks the body-composition endpoint more reliably than scale weight” → “Waist circumference, measured monthly”), cutting the section from roughly ten rendered lines to six.
2. 4.5 — Monitoring cadence shortened: Reduced monitoring_cadence from 274 to 204 characters by tightening the ER’s retest paragraph (“thyroid and metabolic markers retested at 8–12 weeks, then every 6–12 months while use continues” → “thyroid and metabolic markers at 8–12 weeks, then every 6–12 months”) without dropping any retest interval.

Issues 18/08/2026 01:47

1. 1.1 — At-a-glance arsenic clause garbled: [at_a_glance] (QRS lines 437-438) ends “can carry enough iodine to unsettle the thyroid, and arsenic”, which reads as arsenic unsettling the thyroid; the ER Conclusion (line 531) states these as two separate hazards (“can carry enough iodine to unsettle the thyroid … and can concentrate arsenic”).
2. 9.5 — OTC example drugs dropped: The over-the-counter interaction item (QRS lines 600-603) carries only class names, dropping the ER’s named example drugs at line 335 (ibuprofen, naproxen, aspirin for NSAIDs; diphenhydramine, doxylamine for sedating antihistamines), while every other interaction item retains its drug list.

Fixes 18/08/2026 01:47

1. 1.1 — At-a-glance arsenic clause: Rewrote the closing clause from “and arsenic” to “and can concentrate arsenic”, restoring the ER’s two separate hazards; “a smaller rise in blood sugar” was tightened to “a smaller blood-sugar rise” to hold the summary at 59 words.
2. 9.5 — OTC example drugs restored: Expanded the over-the-counter interaction item to “NSAIDs: ibuprofen, naproxen, aspirin; sedating antihistamines: diphenhydramine, doxylamine; iodine-containing expectorants, potassium iodide”, carrying the ER’s named example drugs alongside the class names.